{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:23:13Z","timestamp":1788819793071,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006190","name":"US Department of Veterans Affairs Office of Research & Development","doi-asserted-by":"publisher","award":["1IK2CX002437-01A1"],"award-info":[{"award-number":["1IK2CX002437-01A1"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T16:54:07Z","timestamp":1694105647000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL)"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0416-5115","authenticated-orcid":false,"given":"Helen","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9058-211X","authenticated-orcid":false,"given":"Pankaj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clml.2023.09.001_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.001_bib0002","series-title":"Veterans and Agent Orange: Update 11 (2018)","first-page":"738","year":"2018"},{"issue":"6","key":"10.1016\/j.clml.2023.09.001_bib0003","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1080\/10428194.2017.1375109","article-title":"The impact of agent orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study","volume":"59","author":"Mescher","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2023.09.001_bib0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/OP.21.00258","article-title":"Frontline management of CLL in 2021","volume":"18","author":"Brem","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.clml.2023.09.001_bib0005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/10428194.2023.2190436","article-title":"Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study","volume":"64","author":"Eyre","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.09.001_sbref0006","series-title":"VA ORD 22-D4V","year":"2008"},{"key":"10.1016\/j.clml.2023.09.001_bib0007","unstructured":"Veterans Health Administration Center of Excellence for Suicide Prevention. Joint Department of Veterans Affairs and Department of Defense Mortality Data Repository. 2022. Data compiled from the National Death Index. Available at: https:\/\/www.mirecc.va.gov\/suicideprevention\/documents\/VA_DoD-MDR_Flyer.pdf; Accessed December 6, 2022."},{"issue":"8","key":"10.1016\/j.clml.2023.09.001_bib0008","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2023.09.001_bib0009","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.09.001_bib0010","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.09.001_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.09.001_bib0012","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.09.001_bib0013","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.clml.2023.09.001_bib0014","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.3390\/curroncol28060408","article-title":"Examining treatment patterns and real-world outcomes in chronic lymphocytic leukemia using administrative data in Ontario","volume":"28","author":"Seung","year":"2021","journal-title":"Curr Oncol"},{"issue":"19","key":"10.1016\/j.clml.2023.09.001_bib0015","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.09.001_bib0016","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.09.001_bib0017","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2023.09.001_bib0018","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:53Z","timestamp":1761871373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023015483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023015483"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}